Antiviral Drugs Advisory Committee May 19, 2005
Briefing Information
NDA 021-814 APTIVUS (Tipranavir) 250 mg Capsules
Food and Drug Administration Briefing Information
htm Word
pdf
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Boehringer Ingelheim Briefing Information htm Word pdf
Page updated:
May 19, 2005
|